While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Mineralys Therapeutics, Inc.'s lorundrostat shows promise for treating aldosterone-driven hypertension with FDA approval by 2027. Click for my MLYS stock update.

From Meta, OpenAI, Google, and Databricks to Nvidia and Samsung, numerous new AI capabilities have been announced ...

An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary ...

This came after AstraZeneca Pharma India presented the proposal for ... ABYSS Trial Finds Elevated BP, HR & Deleterious CV Outcomes After Beta blocker Withdrawal Post-MI: ...

AstraZeneca is putting the pedal to the metal to drive up early detection of prostate cancer. The British pharma—which sells Lynparza as a prostate cancer treatment and is also testing its ...

A Google Translate screenshot correctly shows that the name of the pharmaceutical company AstraZeneca, when written as “A stra ze neca,” means “a road to death” in Latin. We reached out to ...

In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective HER2 ...

AstraZeneca and Merck are still leading the pack when it comes to how oncologists perceive makers of cancer drugs, according to a new report from ZoomRx. Though Merck edged out AstraZeneca by a ...